| Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer G Vandekerkhove, JM Lavoie, M Annala, AJ Murtha, N Sundahl, S Walz, ... Nature Communications 12 (1), 184, 2021 | 101 | 2021 |
| BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression E Warner, C Herberts, S Fu, S Yip, A Wong, G Wang, E Ritch, AJ Murtha, ... Clinical Cancer Research 27 (6), 1650-1662, 2021 | 69 | 2021 |
| Activating AKT1 and PIK3CA mutations in metastatic castration-resistant prostate cancer C Herberts, AJ Murtha, S Fu, G Wang, E Schönlau, H Xue, D Lin, ... European urology 78 (6), 834-844, 2020 | 66 | 2020 |
| Identification of hypermutation and defective mismatch repair in ctDNA from metastatic prostate cancer E Ritch, SYF Fu, C Herberts, G Wang, EW Warner, E Schönlau, ... Clinical Cancer Research, 2019 | 66 | 2019 |
| Genomic features of lung-recurrent hormone-sensitive prostate cancer NM Fonseca, K Van der Eecken, C Herberts, S Verbeke, SWS Ng, ... JCO precision oncology 6, e2100543, 2022 | 9 | 2022 |
| Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping EW Warner, K Van der Eecken, AJ Murtha, EM Kwan, C Herberts, J Sipola, ... Nature Cancer, 1-17, 2024 | 6 | 2024 |
| Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. Nat Commun 12: 184 G Vandekerkhove, JM Lavoie, M Annala, AJ Murtha, N Sundahl, S Walz, ... | 4 | 2021 |
| Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer NM Fonseca, C Maurice-Dror, C Herberts, W Tu, W Fan, AJ Murtha, ... Nature Communications 15 (1), 1828, 2024 | 3 | 2024 |
| Evaluating the use of circulating tumor DNA (ctDNA) in patients with urothelial cancer in the context of FGFR-targeted therapy. E Schönlau, DC Müller, G Vandekerkhove, A Murtha, JVW Bacon, C Wells, ... Journal of Clinical Oncology 41 (16_suppl), 4577-4577, 2023 | 2 | 2023 |
| Multi-focal genomic dissection of synchronous primary and metastatic tissue from de novo metastatic prostate cancer E Warner, K Van der Eecken, AJ Murtha, EM Kwan, SW Ng, XE Chen, ... Cancer Research 82 (12_Supplement), 41-41, 2022 | 1 | 2022 |
| Abstract A007: Circulating tumor DNA and tissue staining analyses reveal heterogeneous ERBB2/HER2 status in urothelial cancer G Vandekerkhove, AJ Murtha, DC Müller, K Rostin, C Vasquez-Rios, ... Clinical Cancer Research 30 (10_Supplement), A007-A007, 2024 | | 2024 |
| Abstract A004: Clinical test design affects tumor tissue and ctDNA FGFR gene status in metastatic urothelial cancer: a prospective study DC Müller, G Vandekerkhove, AJ Murtha, JVW Bacon, C Vasquez-Rios, ... Clinical Cancer Research 30 (10_Supplement), A004-A004, 2024 | | 2024 |
| Impact of androgen deprivation therapy (ADT) on circulating tumor DNA (ctDNA) detection in de novo metastatic castration-sensitive prostate cancer (mCSPC). EM Kwan, AJ Murtha, W Tu, C Vasquez Rios, CQ Bernales, SK Arviola, ... Journal of Clinical Oncology 42 (4_suppl), 204-204, 2024 | | 2024 |
| Towards accurate genomics for newly diagnosed metastatic prostate cancer AJ Murtha, AW Wyatt NATURE CANCER, 2024 | | 2024 |
| Abstract IA006: Overcoming complex polyclonality for accurate clinical genotyping in metastatic prostate cancer AW Wyatt, AJ Murtha, E Warner, K Van der Eecken, EM Kwan, C Herberts, ... Cancer Research 83 (11_Supplement), IA006-IA006, 2023 | | 2023 |
| Overcoming complex polyclonality for accurate clinical genotyping in metastatic prostate cancer AW Wyatt, AJ Murtha, E Warner, K Van der Eecken, EM Kwan, C Herberts, ... American-Association-for-Cancer-Research (AACR) Special Conference 83 (11 …, 2023 | | 2023 |
| 4MO Multi-focal genomic dissection of synchronous primary and metastatic tissue from de novo metastatic prostate cancer AJ Murtha, E Warner, K van der Eecken, E Kwan, C Herberts, J Sipola, ... Annals of Oncology 33, S1384, 2022 | | 2022 |
| Development of secondary urothelial carcinoma following complete response to immune checkpoint inhibitors JM Lavoie, G Vandekerkhove, AJ Murtha, G Wang, AW Wyatt, BJ Eigl Urology Case Reports 39, 101762, 2021 | | 2021 |
| Clinical and genomic indolence in lung-recurrent metastatic hormone-sensitive prostate cancer N Fonseca, K Van Der Eecken, C Herberts, S Verbeke, S Ng, N Lumen, ... Global Congress on Prostate and Bladder Cancer 2021, 2021 | | 2021 |
| Genomic features of lung-recurrent hormone sensitive prostate cancer K Van Der Eecken, N Fonseca, C Herberts, S Verbeke, S Ng, N Lumen, ... Belgian Week of Pathology, 2021 | | 2021 |
